Treatment of Kala-azar: Past, Present & Future

Authors

  • HAM Nazmul Ahasan Professor, Department of Medicine, Dhaka Medical College.
  • Fazle Rabbi Mohammed Post Graduate Trainee, Department of Medicine, Dhaka Medical College Hospital.
  • Fazle Rabbi Chowdhury Post Graduate Trainee, Department of Medicine, Dhaka Medical College Hospital.
  • Md Billal Alam Associate Professor, Department of Medicine, Dhaka Medical College

DOI:

https://doi.org/10.3329/jom.v9i2.1438

Abstract

More than 90 percent of cases of kala-azar in the world occur in India, Bangladesh, Nepal, Sudan, and Brazil. Nearly 25 compounds are reported to have anti-leishmanial effects but not all are in use. The pentavalent antimony compounds have remained as mainstay of treatment for nearly 75 years. However, emergence of resistance led to the use of other compounds like amphotericin B, pentamidine, paromomycin, miltefosine etc. Miltefosine is the only oral agent available and recently has been recommended in the National guideline of Bangladesh. But it has a long half-life of 154 hour and this could encourage development of clinical resistance. Further, rapid therapeutic response along with unsupervised treatment can severely affect compliance, and bring a premature end to this very important arsenal against leishmania. Stimaquine is other oral agent coming in near future along with some promising immunotherapeutic agents and of course the possibility of a vaccine. We can assume that in future, combination of drug will be the desirable solution to combat Kala-azar.  

DOI = 10.3329/jom.v9i2.1438

J MEDICINE 2008; 9 : 90-95

Downloads

Download data is not yet available.
Abstract
551
PDF
139

Downloads

How to Cite

Ahasan, H. N., Mohammed, F. R., Chowdhury, F. R., & Alam, M. B. (2008). Treatment of Kala-azar: Past, Present & Future. Journal of Medicine, 9(2), 90–95. https://doi.org/10.3329/jom.v9i2.1438

Issue

Vol. 9 No. 2 (2008)

Section

Review Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).